DeepMed Research

Aspartic acid

Generic Name: Aspartic acid

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₄H_₇NO_₄

CAS Number: 56-84-8

Unique Ingredient Identifier: 30KYC7MIAI

Background: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Indication: There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

Associated Therapies: Amino acid supplementation

Clinical Trials

Vitamin D Oral Gel for Prevention of Radiation Induced Oral Mucositis

Phase 2

Conditions: Oral Mucositis Due to Radiation

Interventions: Drug: vitamin D oral gel
Drug: BBC oral spray
Drug: Miconazole Topical Gel
Drug: Oracure gel
Other: Alkamisr sachets

First Posted Date: 2020-03-13

Last Posted Date: 2020-03-13

Lead Sponsor: Hams Hamed Abdelrahman

Target Recruit Count: 45

Registration Number: NCT04308161

Locations: 🇪🇬
Outpatient clinic of Department of Clinical Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

Phase 2

Completed

Conditions: Vaso-occlusive Crisis
Sickle Cell Disease
Sickle Cell Anemia in Children

Interventions: Drug: Omega 3
Drug: Statins (Cardiovascular Agents)
Drug: Vit D
Drug: Zinc sulfate
Drug: Hydroxy Urea
Drug: Folic Acid Supplementation
Drug: Morphine Sulfate
Procedure: blood transfusion session

First Posted Date: 2020-03-10

Last Posted Date: 2021-01-27

Lead Sponsor: Beni-Suef University

Target Recruit Count: 350

Registration Number: NCT04301336

Locations: 🇪🇬
Faculty of Pharmacy, Beni-Suef university, Banī Suwayf, Egypt
🇪🇬
Health insurance hospital, Banī Suwayf, Egypt
🇪🇬
Faculty of medicine, Beni-suef univeristy - Beni-Seuf university hospital, Banī Suwayf, Egypt

and more 1 locations

Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects

Phase 1

Conditions: Healthy

Interventions: Drug: A dose as CJ-15314
Drug: B dose as CJ-15314
Drug: C dose as CJ-15314
Drug: D dose as CJ-15314
Drug: E dose as CJ-15314
Drug: F dose as CJ-15314
Drug: Placebo

First Posted Date: 2020-03-06

Last Posted Date: 2020-03-06

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 55

Registration Number: NCT04297865

Locations: 🇰🇷
Seoul National University Hospital, Dept. of Clinical Pharmacology, Seoul, Korea, Republic of

Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics

Phase 4

Completed

Conditions: Insulin Resistance
Vitamin D Deficiency
Diabetes Mellitus, Type 2

Interventions: Drug: oral vitamin D

First Posted Date: 2019-12-03

Last Posted Date: 2019-12-03

Lead Sponsor: King Edward Medical University

Target Recruit Count: 106

Registration Number: NCT04183257

Vit D Role in Post Thyroidectomy Hypocalcemia

Early Phase 1

Conditions: Thyroid Diseases

Interventions: Drug: vit D

First Posted Date: 2019-09-19

Last Posted Date: 2019-09-19

Lead Sponsor: Assiut University

Target Recruit Count: 30

Registration Number: NCT04094493

Locations: 🇪🇬
Assiut university, Assiut, Egypt

Treatment of BV With Donaxyl and a Molecular Test of Cure

Completed

Conditions: Bacterial Vaginoses

First Posted Date: 2019-08-15

Last Posted Date: 2019-08-15

Lead Sponsor: Skaraborg Hospital

Target Recruit Count: 58

Registration Number: NCT04057482

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma

Phase 3

Terminated

Conditions: Asthma; Eosinophilic

Interventions: Drug: Treatment C
Drug: Treatment D
Drug: Treatment B
Drug: Treatment A

First Posted Date: 2019-08-08

Last Posted Date: 2022-04-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 810

Registration Number: NCT04049175

Locations: 🇧🇬
Medical Center "Nov Rehabilitatsionen Tsentar" Ltd, Stara Zagora, Bulgaria

Vitamin D in Fatty Liver Disease

Phase 4

Completed

Conditions: Vitamin D Deficiency
Non-alcoholic Fatty Liver Disease

Interventions: Drug: Placebo
Drug: 1,25-Dihydroxyvitamin D

First Posted Date: 2019-07-31

Last Posted Date: 2019-07-31

Lead Sponsor: University Hospital Rijeka

Target Recruit Count: 360

Registration Number: NCT04038853

Vitamin D for Polycystic Ovary Syndrome Clomiphene Resistant Women

Phase 4

Completed

Conditions: PCOS
Vitamin D Deficiency

Interventions: Drug: Vit D
Drug: Metformin
Drug: Clomiphene

First Posted Date: 2019-07-08

Last Posted Date: 2019-07-08

Lead Sponsor: Ain Shams University

Target Recruit Count: 120

Registration Number: NCT04010942

Locations: 🇪🇬
Ain Shams University Maternity hospital, Cairo, Egypt

A Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria

Phase 4

Conditions: Urticaria
Vitamin D Deficiency

Interventions: Drug: Vit D

First Posted Date: 2019-06-19

Last Posted Date: 2019-06-24

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 262

Registration Number: NCT03991845

Locations: 🇮🇳
PGIMER, Chandigarh, India

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy